Increasing complexity of high-grade B-cell lymphomas

    loading  Checking for direct PDF access through Ovid

Abstract

Morphologic heterogeneity is only part of the picture for patients with high-grade B-cell lymphomas, and many of these lymphomas are biologically driven by equally complex variations in genetics and protein expression. In this patient population, novel targeted therapies need to be tested in combination with chemoimmunotherapy in the front-line setting, because the proportion of patients who progress early is so high, and many patients do not appear to be salvageable with further conventional chemotherapy regimens.

Related Topics

    loading  Loading Related Articles